Cost Effectiveness of Erlotinib Versus Gemcitabine/Carboplatin in First-Line Therapy of Advanced EGFR-Mutations Positive Non-Small-Cell Lung Cancer

May 1, 2016, 00:00
10.1016/j.jval.2016.03.1603
https://www.valueinhealthjournal.com/article/S1098-3015(16)01671-5/fulltext
Title : Cost Effectiveness of Erlotinib Versus Gemcitabine/Carboplatin in First-Line Therapy of Advanced EGFR-Mutations Positive Non-Small-Cell Lung Cancer
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01671-5&doi=10.1016/j.jval.2016.03.1603
First page : A152
Section Title : Cancer - Cost Studies
Open access? : No
Section Order : 324
Categories :
Tags :
Regions :
ViH Article Tags :